GCP
RNAC icon

GSA Capital Partners’s Cartesian Therapeutics RNAC Stock Holding History

GSA Capital Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-77,227
Closed -$557K – 2098
2025
Q4 		$557K Sell
77,227
-8,868
-10% -$71.7K 0.05% 736
2025
Q3 		$880K Buy
86,095
+44,493
+107% +$500K 0.07% 480
2025
Q2 		$432K Buy
41,602
+24,811
+148% +$264K 0.03% 1023
2025
Q1 		$221K Buy
+16,791
New +$300K 0.02% 1346
2024
Q1 		– Sell
-4,483
Closed -$93K – 1915
2023
Q4 		$93K Sell
4,483
-5,192
-54% -$155K 0.01% 1401
2023
Q3 		$308K Buy
+9,675
New +$323K 0.03% 1060
2023
Q2 		– Sell
-11,091
Closed -$462K – 1880
2023
Q1 		$462K Sell
11,091
-1,312
-11% -$61.7K 0.05% 770
2022
Q4 		$420K Sell
12,403
-11,757
-49% -$500K 0.05% 709
2022
Q3 		$1.19M Sell
24,160
-2,408
-9% -$132K 0.16% 101
2022
Q2 		$1.04M Buy
26,568
+21,518
+426% +$638K 0.16% 130
2022
Q1 		$186K Buy
+5,050
New +$316K 0.03% 1190
2021
Q1 		– Sell
-2,038
Closed -$185K – 1431
2020
Q4 		$185K Buy
+2,038
New +$177K 0.03% 1012
2019
Q3 		– Sell
-2,782
Closed -$149K – 1667
2019
Q2 		$149K Sell
2,782
-3,131
-53% -$213K 0.02% 1292
2019
Q1 		$420K Buy
+5,913
New +$375K 0.04% 799

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's RNAC Position: Q1 2026 in Review

GSA Capital Partners sold out of Cartesian Therapeutics (RNAC) in Q1 2026, closing a stake of 77,227 shares — an estimated $557K sold.

GSA Capital Partners first reported a position in RNAC in Q1 2019 and held it in 14 quarters. The position peaked at $1.19M in Q3 2022. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • GSA Capital Partners reported no remaining Cartesian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 77,227 Cartesian Therapeutics shares in Q1 2026, an estimated $557K.
  • GSA Capital Partners first reported a position in Cartesian Therapeutics in Q1 2019 and held it in 14 quarters.
  • GSA Capital Partners's Cartesian Therapeutics position peaked at $1.19M in Q3 2022.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.